Fengycin inhibits the growth of the human lung cancer cell line 95D through reactive oxygen species production and mitochondria-dependent apoptosis
Authors:
- 1 July 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (6) , 587-598
Abstract
To investigate the antitumor activity and action mechanism of fengycin using the human lung cancer cell line 95D. The antitumor activity of fengycin was tested in vitro and in vivo. Reactive oxygen species production, Ca2+ uptake, and mitochondrial membrane potential loss induced by fengycin in 95D cells were measured by flow cytometry and a laser confocal microscope. Lactate dehydrogenase release and caspase activity in fengycin-treated 95D cells were assayed using cytotoxicity detection kits. Apoptosis triggered by fengycin was identified by 4,6-diamidino-2-phenylindole (DAPI) staining and flow cytometry. The effects of fengycin on cell-cycle and apoptosis-related proteins were evaluated by quantitative reverse-transcription PCR and western blot. Treatment with fengycin not only significantly decreased cell proliferation in various cancer cell lines including 95D but inhibited the growth of xenografted 95D cells in nude mice. Fengycin also induced reactive oxygen species production and Ca2+ uptake, as well as lactate dehydrogenase release and mitochondrial membrane potential loss. Further experiments showed that fengycin could trigger apoptosis in 95D cells and cause cell-cycle arrest at the G0/G1 stage by downregulating cyclin D1 and cyclin-dependent kinase 4 (CDK4). While investigating caspase activity and the expression of apoptosis-related proteins, fengycin was found to induce apoptosis in 95D cells through the mitochondrial pathway, evidenced by increased caspase activity, Bax expression, and cytochrome c release into the cytoplasm, as well as decreased Bcl-2 levels. Fengycin can inhibit the growth of the cancer cell line 95D by regulating the cell cycle and promoting apoptosis, suggesting that it may have potential as an anticancer treatment.Keywords
This publication has 24 references indexed in Scilit:
- ROS-Ca2+ is associated with mitochondria permeability transition pore involved in surfactin-induced MCF-7 cells apoptosisChemico-Biological Interactions, 2011
- A cationic amphiphilic peptide ABP-CM4 exhibits selective cytotoxicity against leukemia cellsPeptides, 2010
- Identification of fengycin homologues from Bacillus subtilis with ESI-MS/CIDJournal of Microbiological Methods, 2009
- Effect of Fengycin, a Lipopeptide Produced by Bacillus subtilis, on Model BiomembranesBiophysical Journal, 2008
- Bacillus lipopeptides: versatile weapons for plant disease biocontrolTrends in Microbiology, 2008
- The Iturin and Fengycin Families of Lipopeptides Are Key Factors in Antagonism of Bacillus subtilis Toward Podosphaera fuscaMolecular Plant-Microbe Interactions®, 2007
- Surfactin from Bacillus subtilis displays anti‐proliferative effect via apoptosis induction, cell cycle arrest and survival signaling suppressionFEBS Letters, 2007
- Deficiency of Disulfide Bonds Facilitating Fibrillogenesis of EndostatinJournal of Biological Chemistry, 2006
- Potential applications of microbial surfactants in biomedical sciencesTrends in Biotechnology, 2004
- Fengycin - A novel antifungal lipopeptide antibiotic produced by Bacillus subtilis F-29-3.The Journal of Antibiotics, 1986